Publicaciones Científicas
Uno de los principales fines de la Fundación es el de
capacitar a profesionales y estimular la investigación
científica, ahondando las causas y buscando nuevas formas
y/o métodos en el tratamiento de enfermedades oncológicas,
con el fin de reducir la incidencia de la enfermedad y
encontrar su cura.
Para ello, en el Área de Investigación se llevan a cabo los
estudios epidemiológicos, pre clínicos y clínicos, lo cual
nos permite un mejor conocimiento para el tratamiento y el
desarrollo de nuevas drogas.
PUBLICACIONES
2022 ASCO ANNUAL MEETING
-Update to role of the neutrophil lymphocyte ratio in
patients with advanced NSCLC undergoing immunotherapy.
2021 ANNUAL MEETING
-Analysis of the relationship between different prognosis
factors in patients with advanced colon cancer and
progression-free survival.
J Clin Oncol 39, 2021 (suppl 15; abstr
e15518)
-Neutrophil-lymphocyte radio (NLR) as a possible predictive
factor in patients with advanced NSCLC WHO received
immunotherapy.
J Clin Oncol 39, 2021 (suppl 15; abstr
e21042)
-Relationship between neutrophils/lymphocytes and tumor
infiltrating lymphocytes stroma in patients with invasive
muscle bladder cancer and the response to treatment.
J Clin Oncol 39, 2021 (suppl 15; abstr
e16513)
-First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two
cycles of chemotherapy (chemo) versus chemo alone (4 cycles)
in patients with advanced non-small cell lung cancer
(NSCLC): Two-year update from CheckMate 9LA.
J Clin Oncol 39, 2021 (suppl 15; abstr
9000)
-Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN)
for advanced renal cell carcinoma (aRCC): Outcomes by
sarcomatoid histology and updated trial results with
extended follow-up of CheckMate 9ER.
J Clin Oncol 39, 2021 (suppl 6; abstr
308)
-Safety of darolutamide (DARO) for nonmetastatic
castration-resistant prostate cancer (nmCRPC) from extended
follow-up in the phase III ARAMIS trial.
J Clin Oncol 39, 2021 (suppl 6; abstr
239)
2020 ASCO ANNUAL MEETING
-Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of
platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as
first-line (1L) treatment (tx) for stage IV/recurrent
non-small cell lung cancer (NSCLC): CheckMate 9LA..
J Clin Oncol 38: 2020 (suppl; abstr 9501)
-Final analysis of the CheckMate 025 trial comparing
nivolumab (NIVO) versus everolimus (EVE) with >5 years of
follow-up in patients with advanced renal cell carcinoma
(aRCC).
J Clin Oncol 38, 2020 (suppl 6; abstr
617)
2019 ASCO ANNUAL MEETING
-A randomized, multicenter clinical trial to determine the
efficacy and safety of pegfilgrastim (GEMA BIOTECH) compared
to pegfilgrastim (Roche) for prevention of chemotherapy
induced neutropenia in patients with breast cancer.
J Clin Oncol 37, 2019 (suppl; abstr 3113)
2018 ASCO ANNUAL MEETING
-Lympho-platelets relationship as a prognostic factor for
advanced colorectal cancer.
J Clin Oncol 36, 2018 (suppl; abstr
e15667)
2017 ASCO ANNUAL MEETING
-Tumor-infiltrating lymphocytes as a prognostic factor in
patients with stage I to III breast cancer.
J Clin Oncol 35, 2017 (suppl; abstr
e12042)
-Analysis of lymphocyte-neutrophil relationship in patients
with advanced kidney cancer and the response to one-line
treatment with target therapies.
J Clin Oncol 35, 2017 (suppl; abstr
e23034)
ESMO VIRTUAL CONGRESS 2021
-696O_PR - Nivolumab + cabozantinib vs sunitinib in
first-line treatment for advanced renal cell carcinoma:
First results from the randomized phase III CheckMate 9ER
trial
Annals of Oncology (2020) 31 (suppl_4):
S1142-S1215. 10.1016/annonc/annonc325
ESMO VIRTUAL CONGRESS 2020
-LBA59 - First-line nivolumab (NIVO) + ipilimumab (IPI)
combined with 2 cycles of platinum-based chemotherapy
(chemo) vs 4 cycles of chemo in advanced non-small cell lung
cancer (NSCLC): Patient-reported outcomes (PROs) from
CheckMate 9L
Annals of Oncology (2020) 31 (suppl_4): S1142-S1215.
10.1016/annonc/annonc325
EUROPEAN LUNG CANCER CONGRESS 2021
-98O - First-line nivolumab (NIVO) + ipilimumab (IPI) + 2
cycles chemotherapy (chemo) vs 4 cycles chemo in advanced
non-small cell lung cancer (aNSCLC): association of blood
and tissue tumor mutational burden (TMB) with efficacy in
CheckMate 9LA
Journal of Thoracic Oncology (2021) 16
(suppl_4): S748-S802.
IASLC 19th World Conference on Lung Cancer TORONTO CANADA
-CheckMate 227: Patient Reported Outcomes of First-Line
Nivolumab + Ipilimumab in High Tumor Mutational Burden
Advanced NSCLC
https://doi.org/10.1016/j.jtho.2018.08.261
XXV CONGRESO ARGENTINO E INTERNACION DE ONCOLOGIA CLINICA 2021
-Impacto de la pandemia por COVID-19 en la consulta, diagnóstico y tratamiento en pacientes oncológicos del Instituto Oncológico de Córdoba.
THE NEW ENGLAND JOURNAL OF MEDICINE 2021
- Nivolumab más cabozantinib versus sunitinib para el
carcinoma de células renales avanzado.
N Engl J Med 2021; 384:829-841 DOI:
10.1056/NEJMoa2026982
THE NEW ENGLAND JOURNAL OF MEDICINE 2019
-Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung
Cancer
N Engl J Med 2019; 381:2020-2031, DOI: 10.1056/NEJMoa1910231
JTO - JOURNAL OF THORACIC ONCOLOGY
-First-line Nivolumab + Ipilimumab + Chemo in Patients With
Advanced NSCLC and Brain Metastases: Results From CheckMate
9LA
Journal of Thoracic OncologyVol. 16Issue
10SupplementS862Published in issue: October 2021
-Durvalumab in Locally-Advanced NSCLC in LATAM: Real World
Data from Patients Included in the Early Access Program
Journal of Thoracic OncologyVol. 16Issue
3SupplementS369Published in issue: March 2021
-First-line nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles
chemotherapy (chemo) vs 4 cycles chemo in advanced non-small
cell lung cancer (aNSCLC): Association of blood and tissue
tumor mutational burden (TMB) with efficacy in CheckMate 9LA
Journal of Thoracic OncologyVol. 16Issue
4SupplementS750–S751Published in issue: April 2021
-Nivolumab (NIVO) + ipilimumab (IPI) + 2 Cycles of
Platinum-Doublet Chemotherapy (Chemo) vs. 4 Cycles Chemo as
First-Line (1L) Treatment) for Stage IV/Recurrent Non-Small
Cell Lung Cancer (NSCLC): CheckMate 9LA
Journal of Thoracic OncologyVol. 16Issue
1SupplementS2Published in issue: January 2021
-Update of the Analysis of the Status of Lymphocyte
Infiltration in Patients with NSCLC
Journal of Thoracic OncologyVol. 14Issue
11SupplementS1180–S1181Published in issue: November 2019
-Update of the Analysis of the Status of Lymphocyte
Infiltration in Patients with NSCLC
Journal of Thoracic OncologyVol. 14Issue
10SupplementS962Published in issue: October 2019
-CheckMate 227: Patient-Reported Outcomes of First-Line
Nivolumab + Ipilimumab in High Tumor Mutational Burden
Advanced NSCLC
Journal of Thoracic OncologyVol. 13Issue
10SupplementS332Published in issue: October 2018
-Analysis of Toxicities in Patients with Lung Cancer
Compared Other Tumors in Inmune Therapy in Our Institution
Journal of Thoracic OncologyVol. 13Issue
9SupplementS172–S173Published in issue: September 2018
-Treatment of Advanced Non–Small Cell Lung Cancer (NSCLC) in
Patients (P) Older Than 70
Journal of Thoracic OncologyVol. 13Issue
9SupplementS174–S175Published in issue: September 2018
-Predictive Factors of Brain Metastases Development in
Non-Small Cells Lung Cancer (NSCLC)
Journal of Thoracic OncologyVol. 13Issue
9SupplementS176Published in issue: September 2018
-Relationship Between the Expression of pdl1 and the Tumor
Infiltrating Lymphocytes in Patients with Advanced Lung
Cancer
Journal of Thoracic OncologyVol. 13Issue
9SupplementS177–S178Published in issue: September 2018
-Analysis of the Status of Lymphocyte Infiltration in
Patients Diagnosed with Non–Small Cell Lung Cancer
Journal of Thoracic OncologyVol. 13Issue
9SupplementS168Published in issue: September 2018
-Comparative Study of Chemotherapy Regimens Based on
Platinum and Its Different Toxicities in Patients With
Advanced NSCLC: Track: Advanced NSCLC
Journal of Thoracic OncologyVol. 11Issue
10SupplementS207Published in issue: October 2016
-Delays in the Diagnosis and Treatment of Lung Cancer:
Track: Prevention, Early Detection, Epidemiology and Tobacco
Control
Journal of Thoracic OncologyVol. 11Issue
10SupplementS185Published in issue: October 2016
-Relationship Between TILs and Neutrophil-Lymphocyte Ratio
as a Prognostic Factor in Advanced NSCLC: Track: Advanced
NSCLC
Journal of Thoracic OncologyVol. 11Issue
10SupplementS206Published in issue: October 2016
THE LANCET – Medical Journal
-First-line nivolumab plus ipilimumab combined with two
cycles of chemotherapy in patients with non-small-cell lung
cancer (CheckMate 9LA): an international, randomised,
open-label, phase 3 trial
The Lancet OncologyVol. 22No. 2p198–211Published: January
18, 2021
-Docetaxel and dasatinib or placebo in men with metastatic
castration-resistant prostate cancer (READY): a randomised,
double-blind phase 3 trial
The Lancet OncologyVol. 14No. 13p1307–1316Published:
November 8, 2013